ClinicalTrials.gg
TerminatedNCT05240560Updated Aug 9, 2024

Proof of Concept Study Evaluating BP1.3656 in Patients With Fatigue Following Ischemic Stroke

A Phase 2 interventional study of BP1.3656 in Fatigue, sponsored by Bioprojet. Terminated at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-09.

Sponsored by Bioprojet · Phase 2, Interventional, and Treatment

Why this study was terminated
Lack of recruitment
Phase
Phase 2
Study type
Interventional
Enrollment
5
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Multicenter, randomized, double blind, parallel-group, placebo-controlled proof of concept study evaluating efficacy and safety of BP1.3656 in patients with fatigue following ischemic stroke.

02

Conditions studied

  • Fatigue

Browse trials for

Keywords

  • Post-stroke fatigue
03

In context

Fatigue

2,229 studies on the registry are indexed under Fatigue; 426 are open to participants now.

This study's enrollment of 5 is below the median of 54 across 1,757 interventional studies indexed under Fatigue.

Browse Fatigue studies →

Lead sponsor

Bioprojet is the lead sponsor of 29 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females 18 years old or more;
  • Diagnosis of ischemic stroke at least one month and not more than six months prior to screening;
  • Persistent fatigue since the stroke with a score ≥ 50 across all domains of the Multidimensional Fatigue Inventory (MFI-20);
  • Modified Rankin Score (mRS) \< 3;
  • Capability to participate in all study tests according to the investigator;
  • Patient must voluntarily express a willingness to participate in this study, sign and date an prior to any study specific procedure;
  • Females of must have a negative pregnancy test performed at the screening and randomization visits and use a medically accepted effective method of , agree to continue this method for the duration of the study up until three weeks after last treatment intake.

Exclusion criteria

Exclusion Criteria:

  • Any identified etiology for fatigue other than stroke (except post-stroke depression) according to the investigator;
  • History of psychosis;
  • Current severe psychiatric disorder, e.g. schizophrenia, bipolar disorder, severe depression, or organic brain syndrome preventing the patients from completing study assessments;
  • Patients at risk of suicide according to the investigator;
  • Major cognitive disorders, dementia according to the investigator;
  • History of epilepsy or seizures disorder;
  • History of alcohol or drugs (i.e. cannabis, cocaine, amphetamines or opioids) (ab)use/dependence within the 12 months prior to screening or with a positive drug test at screening;
  • \<60 mL/min/1.73m² according to Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula;
  • cardiovascular abnormalities (including clinically relevant abnormalities) or, clinically significant hematological, neurological, endocrine abnormalities, severe hepatic impairment or Liver Function Tests (ASAT, ALAT) > 3 , or abnormal clinical laboratory results (in most cases > 3ULN);
  • Other active clinically significant illness, infection, acid-related gastric disorder, or neoplastic pathology within the last 3 years (patients with fully cured non-melanoma skin cancer or in-situ carcinoma of the cervix are eligible) which could interfere with the study conduct or counter-indicate the study treatments or place the patient at risk during the trial or compromise his/her study participation.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    BP1.3656

    1 tablet of 30 microgram (µg), 60µg or 90µg of BP1.3656 per day

    Drug: BP1.3656

  • Placebo comparator
    Placebo

    1 tablet of matching placebo per day

    Drug: BP1.3656

Interventions

  • DrugBP1.3656

    Histamine H3 receptor antagonist/inverse agonist

06

What researchers measure

Primary outcomes

  1. Multidimensional Fatigue Inventory (MFI-20) global score

    20-item self-report instrument designed to measure fatigue experienced by the participant lately scored from 20 to 100. Higher scores show higher levels of fatigue.

    Time frame: Week 8

Other outcomes

  1. Incidence of Treatment-Emergent Adverse Events (AEs) as assessed by AEs collection

    Safety assessment of BP1.3656 based on adverse events (AEs) reporting during treatment period.

    Time frame: Week 8

  2. Change in Systolic blood pressure (BP) measurement

    Safety assessment of BP1.3656 based on the measurement of systolic blood pressure in units of millimeters of mercury (mmHg)

    Time frame: From baseline to Week 8

  3. Change in Diastolic blood pressure (BP) measurement

    Safety assessment of BP1.3656 based on the measurement of Diastolic blood pressure in units of millimeters of mercury (mmHg)

    Time frame: From baseline to Week 8

  4. Change in pulse

    Safety assessment of BP1.3656 based on the measurement of pulse in beats/minute

    Time frame: From baseline to Week 8

07

Study locations

2 sites
  • Hôpital Pellegrin - CHU BORDEAUX
    Bordeaux, 33076, France
  • Inselspital Berne
    Berne, 3010, Switzerland
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2023 to primary completion in Feb 2024, 12 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2022
First posted
Feb 15, 2022
StartActual
Jan 20, 2023
Primary completionActual
Feb 8, 2024
CompletionActual
Feb 8, 2024
Last update
Aug 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05240560
Lead sponsor
Bioprojet
Responsible party
Sponsor
First posted
Feb 15, 2022
Start date
Jan 20, 2023
Primary completion
Feb 8, 2024
Completion
Feb 8, 2024
Last update
Aug 9, 2024

Study contacts

Claudio Bassetti, MD, Prof.
principal investigator · Inselspital Bern, Department of Neurology, Bern, Switzerland

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion